Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation

  • Aldo J Montano-Loza
  • Vincenzo Ronca
  • Maryam Ebadi
  • Bettina E Hansen
  • Gideon Hirschfield
  • Saleh Elwir
  • Mohamad Alsaed
  • Piotr Milkiewicz
  • Maciej K Janik
  • Hanns-Ulrich Marschall
  • Maria Antonella Burza
  • Cumali Efe
  • Ali Rıza Calışkan
  • Murat Harputluoglu
  • Gökhan Kabaçam
  • Débora Terrabuio
  • Fernanda de Quadros Onofrio
  • Nazia Selzner
  • Alan Bonder
  • Albert Parés
  • Laura Llovet
  • Murat Akyıldız
  • Cigdem Arikan
  • Michael P Manns
  • Richard Taubert
  • Anna-Lena Weber
  • Thomas D Schiano
  • Brandy Haydel
  • Piotr Czubkowski
  • Piotr Socha
  • Natalia Ołdak
  • Nobuhisa Akamatsu
  • Atsushi Tanaka
  • Cynthia Levy
  • Eric F Martin
  • Aparna Goel
  • Mai Sedki
  • Irena Jankowska
  • Toru Ikegami
  • Maria Rodriguez
  • Martina Sterneck
  • Christina Weiler-Normann
  • Christoph Schramm
  • Maria Francesca Donato
  • Ansgar Lohse
  • Raul J Andrade
  • Vilas R Patwardhan
  • Bart van Hoek
  • Maaike Biewenga
  • Andreas E Kremer
  • Yoshihide Ueda
  • Mark Deneau
  • Mark Pedersen
  • Marlyn J Mayo
  • Annarosa Floreani
  • Patrizia Burra
  • Maria Francesca Secchi
  • Benedetta Terziroli Beretta-Piccoli
  • Marco Sciveres
  • Giuseppe Maggiore
  • Syed-Mohammed Jafri
  • Dominique Debray
  • Muriel Girard
  • Florence Lacaille
  • Ellina Lytvyak
  • Andrew L Mason
  • Michael Heneghan
  • Ye Htun Oo
  • International Autoimmune Hepatitis Group (IAIHG)

Related Research units

Abstract

BACKGROUND & AIMS: Autoimmune hepatitis can recur after liver transplantation (LT), though the impact of recurrence on patient and graft survival has not been well characterized. We evaluated a large, international, multicenter cohort to identify the probability and risk factors associated with recurrent AIH and the association between recurrent disease and patient and graft survival.

METHODS: We included 736 patients (77% female, mean age 42±1 years) with AIH who underwent LT from January 1987 through June 2020, among 33 centers in North America, South America, Europe and Asia. Clinical data before and after LT, biochemical data within the first 12 months after LT, and immunosuppression after LT were analyzed to identify patients at higher risk of AIH recurrence based on histological diagnosis.

RESULTS: AIH recurred in 20% of patients after 5 years and 31% after 10 years. Age at LT ≤42 years (hazard ratio [HR] 3.15; 95% CI 1.22-8.16; p = 0.02), use of mycophenolate mofetil post-LT (HR 3.06; 95% CI 1.39-6.73; p = 0.005), donor and recipient sex mismatch (HR 2.57; 95% CI 1.39-4.76; p = 0.003) and high IgG pre-LT (HR 1.04; 95% CI 1.01-1.06; p = 0.004) were associated with higher risk of AIH recurrence after adjusting for other confounders. In multivariate Cox regression, recurrent AIH (as a time-dependent covariate) was significantly associated with graft loss (HR 10.79, 95% CI 5.37-21.66, p <0.001) and death (HR 2.53, 95% CI 1.48-4.33, p = 0.001).

CONCLUSION: Recurrence of AIH following transplant is frequent and is associated with younger age at LT, use of mycophenolate mofetil post-LT, sex mismatch and high IgG pre-LT. We demonstrate an association between disease recurrence and impaired graft and overall survival in patients with AIH, highlighting the importance of ongoing efforts to better characterize, prevent and treat recurrent AIH.

LAY SUMMARY: Recurrent autoimmune hepatitis following liver transplant is frequent and is associated with some recipient features and the type of immunosuppressive medications use. Recurrent autoimmune hepatitis negatively affects outcomes after liver transplantation. Thus, improved measures are required to prevent and treat this condition.

Bibliographical data

Original languageEnglish
ISSN0168-8278
DOIs
Publication statusPublished - 07.2022

Comment Deanary

Copyright © 2022 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

PubMed 35143897